SecBot SecBot
144 ·Filed Jun 30, 2026

HRMY

Harmony Biosciences Holdings, Inc.
BEARISH
Impact 5/10
Horizondays Processed4mo ago SEC0001950047-26-006634
Form 144, notice of proposed sale of securities
Actionable Insight ▼ Bearish

Track whether the sale actually executes, large insider selling by a former officer over two months may signal reduced conviction or planned diversification. Monitor for any material non-public catalysts (upcoming data readouts, guidance updates). Consider the selling into the current bullish analyst consensus (65% buy) as a potential contrarian signal.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$36.00
T+0 close · Jun 30, 2026 · via day close
Latest settled
−0.39%
T+20 · $35.86
Vs SPY
+1.80%
α at T+20
Next horizon
T+60
due 8w ago
  1. T+0 · Jul 1 $36.00entry
  2. T+1 · 5mo ago +3.50%α +3.63% · $37.26
  3. T+5 · 4mo ago +6.28%α +6.02% · $38.26
  4. T+20 · 4mo ago −0.39%α +1.80% · $35.86
  5. T+60 · due 8w ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Former officer Sandip Kapadia filed a Form 144 notice to sell 50,000 shares of Harmony Biosciences, valued at approximately $1.8M. This follows a string of recent sales by Kapadia in May and June 2026 totaling approximately $4.5M, raising concerns about insider conviction ahead of potential catalysts.

Key Facts

  • Former officer Sandip Kapadia filed Form 144 to sell 50,000 shares valued at ~$1.8M.
  • Kapadia executed prior sales: 45,594 shares on 06/26 (~$1.6M), 4,406 on 06/24 (~$0.15M), 27,960 on 06/09 (~$0.94M), 2,101 on 06/05 (~$0.07M), 7,064 on 06/04 (~$0.23M), and 45,481 on 05/08 (~$1.43M).
  • Total recent sales by this insider exceed $4.5M in aggregate.
  • The proposed sale is for 50,000 shares (no remaining holdings disclosed in filing).
  • HRMY market cap is $2.1B; the proposed block is ~0.09% of market cap.

Financial Impact

Proposed sale of 50,000 shares valued at ~$1.8M, plus ~$4.5M in prior sales since May 2026, total insider cash-out ~$6.3M.

insider sellingdilution

Risk Factors

  • Form 144 is intent to sell, execution is not guaranteed.
  • Insider may have tax or estate-planning motives unrelated to company outlook.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
65% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006634
Document: 0001950047-26-006634-index.html0001950047-26-006634
Document: 0001950047-26-006634.txt0001950047-26-006634

US Market Status

Market Closed · Opens in 7h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026